Reactive oxygen species-powered cancer immunotherapy: Current status and challenges
Journal of Controlled Release · 2023-04 · 356 · 623-648
DOI: 10.1016/j.jconrel.2023.02.040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2023-04. Verfasst von Mengying He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China. Hauptthemen laut MEDLINE: Photochemotherapy, Cancer Vaccines, Neoplasms. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 162 Literaturangaben.
Abstract (Originalsprache)
Reactive oxygen species (ROS) are crucial signaling molecules that can arouse immune system. In recent decades, ROS has emerged as a unique therapeutic strategy for malignant tumors as (i) it can not only directly reduce tumor burden but also trigger immune responses by inducing immunogenic cell death (ICD); and (ii) it can be facilely generated and modulated by radiotherapy, photodynamic therapy, sonodynamic therapy and chemodynamic therapy. The anti-tumor immune responses are, however, mostly downplayed by the immunosuppressive signals and dysfunction of effector immune cells within the tumor microenvironment (TME). The past years have seen fierce developments of various strategies to power ROS-based cancer immunotherapy by e.g. combining with immune checkpoints inhibitors, tumor vaccines, and/or immunoadjuvants, which have shown to potently inhibit primary tumors, metastatic tumors, and tumor relapse with limited immune-related adverse events (irAEs). In this review, we introduce the concept of ROS-powered cancer immunotherapy, highlight the innovative strategies to boost ROS-based cancer immunotherapy, and discuss the challenges in terms of clinical translation and future perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
- Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China; School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI),…
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Joint International Research Laboratory of Carbon-Based Functional Materials and Devices, S…
- Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China. Electronic address: dawei.ding@suda.edu.cn.
- Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China; Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials…
Zitieren
APA
He, M., Wang, M., Xu, T., Zhang, M., Dai, H., Wang, C., Ding, D., & Zhong, Z. (2023). Reactive oxygen species-powered cancer immunotherapy: Current status and challenges. Journal of Controlled Release, 356, 623-648. https://doi.org/10.1016/j.jconrel.2023.02.040
Vancouver
He M, Wang M, Xu T, Zhang M, Dai H, Wang C, et al. Reactive oxygen species-powered cancer immunotherapy: Current status and challenges. Journal of Controlled Release. 2023;356:623-648. doi:10.1016/j.jconrel.2023.02.040
BibTeX
@article{He2023,
author = {He, Mengying and Wang, Mengyuan and Xu, Tao and Zhang, Mengyao and Dai, Huaxing and Wang, Chao and Ding, Dawei and Zhong, Zhiyuan},
title = {Reactive oxygen species-powered cancer immunotherapy: Current status and challenges},
journal = {Journal of Controlled Release},
year = {2023},
volume = {356},
pages = {623--648},
doi = {10.1016/j.jconrel.2023.02.040}
}
EUVIMED